Infect Chemother.  2016 Jun;48(2):143-144. 10.3947/ic.2016.48.2.143.

The Importance of the Early and Appropriate Treatment of Anaerobic Bacteremia Patients

• Kim YA

• KMID: 2327984
• DOI: http://doi.org/10.3947/ic.2016.48.2.143

Abstract

No abstract available.

MeSH Terms

Bacteremia*
Humans

Reference

1. Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015; 31:4–10.

2. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. M11-A8. 8th ed. Wayne, PA: CLSI;2012.

3. Kim J, Lee Y, Park Y, Kim M, Choi JY, Yong D, Jeong SH, Lee K. Anaerobic bacteremia: impact of inappropriate therapy on mortality. Infect Chemother. 2016; 48:91–98.

4. Umemura T, Hamada Y, Yamagishi Y, Suematsu H, Mikamo H. Clinical characteristics associated with mortality of patients with anaerobic bacteremia. Anaerobe. 2016; 39:45–50.

5. Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis. 1998; 26:1413–1417.

6. Lee Y, Park Y, Kim M, Uh Y, Kim MS, Lee K. Multicenter study of antimicrobial susceptibility of anaerobic bacteria in Korea in 2012. Ann Lab Med. 2015; 35:479–486.

7. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 2013; 26:526–546.

8. Thermo scientific. TREK diagnostic system: Sensititre. Accessed 17 June 2016. Available: http://www.trekds.com/products/sensititre/c_pltformats.asp.